Adhesives Market Expansion
H.B. Fuller Acquires Advanced Medical Solutions, Targeting Higher Growth in Medical Market
H.B. Fuller (NYSE: FUL) has agreed to buy UK-listed Advanced Medical Solutions Group (AMS) for £2.85 per share in cash, valuing the deal at roughly £715 million (~$908 million), according to Business Wire. The offer is recommended by the AMS board, meaning AMS directors are telling shareholders to accept it.
The deal is the largest move yet by H.B. Fuller to break into high-margin medical technology. It adds an estimated $300 million in annual revenue and expands the company's total addressable market from $80 billion to $95 billion, according to Business Wire.
A Six-Week Battle Ending in a Recommended Bid
The path to this deal was anything but smooth. H.B. Fuller made an unsolicited, all-cash approach to AMS on April 30, 2026. AMS went public about the proposal on May 21, starting a formal offer clock under UK takeover rules. A first deadline of June 18 came and went without a deal, and regulators granted a two-week extension to July 2, according to UK Marketscreener.
H.B. Fuller locked in the deal on June 25 — just hours after reporting strong Q2 earnings showing a 9% rise in Adjusted EBITDA and record operating cash flow. CEO Celeste Mastin called it "a rare opportunity to advance the evolution of our portfolio," adding that medical is "a core strategic growth market" because of its "durable demand trends" and "high regulatory-based entry barriers."
What H.B. Fuller Gets: Surgical Glue and $55M in Savings
AMS makes specialized surgical adhesives, wound-care tapes, dressings, and formulated biosurgicals — products surgeons use to seal tissue instead of stitches. These are high-barrier products. Competing requires years of regulatory approvals, which keeps rivals out and margins high. AMS employs 1,800 people and has a dedicated R&D team of over 75 specialists.
H.B. Fuller expects to capture $55 million (£41 million) in combined revenue and cost synergies annually by 2031, according to Business Wire. Most savings will come from cutting public-company overhead and consolidating factories across the UK, Italy, and the U.S. At 12.9x pre-synergy EBITDA, the deal looks pricey. But management says that falls below 8x once synergies are counted.
Activist Investor Calls the Deal a 'Quasi-Transformational' Mistake
Not everyone is cheering. Ancora Holdings, an activist fund owning more than 2% of H.B. Fuller, publicly opposed the deal on May 23. The group labeled it "quasi-transformational" and "out of management's depth," warning that adding more debt could push H.B. Fuller's leverage ratio above 4.0x — a level that could threaten its credit rating.
H.B. Fuller fired back on May 26, pointing to 13 successful acquisitions since early 2023. Management has pledged to bring its net debt-to-EBITDA ratio back to between 2.5x and 3.0x within two years of closing the deal. UBS raised its price target for H.B. Fuller to $71 in mid-June but flagged leverage as a potential "overhang" on the stock.
A New Business Unit Signals a Bigger Strategic Shift
H.B. Fuller will create a brand-new global business unit specifically for medical. That unit will be reported separately in financial statements. The move is designed to give investors a clear view of the medical segment's growth and margins, separate from the company's older industrial adhesive operations.
The deal is governed by the UK City Code on Takeovers and Mergers and still needs regulatory clearances before it closes. H.B. Fuller is advised by Goldman Sachs and Perella Weinberg Partners. AMS is advised by Evercore and Investec Bank. AMS shares surged toward the 285p offer price on the day of the announcement.
Sentiment
NeutralPublishers
5
Articles
4
Reach
5
